Quinolones: Recent structural and clinical developments

Iranian Journal of Pharmaceutical Research

Volumn 4, Issue 3, 2005, Pages 123-136

  Emami, Saeed ^a   Shafiee, Abbas ^b   Foroumadi, Alireza ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibacterial agents; Quinolones; Structure activity relationships

Indexed keywords

EID: 85113210462     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: 10.22037/IJPR.2010.628     Document Type: Article

References (75)

1. Gootz TD, Brighty KE. Chemistry and mechanism of action of the quinolone antibacterials. In: Andriole VT (ed.), The Quinolones. 2nd ed. Academic Press, San Diego (1998) 29-80
2. Andriole VT. The future of the quinolones. Drugs (1999) 58 (Suppl 2): 1-5
3. Hooper DC. Mode of action of fluoroquinolones. Drugs (1999) 58 (Suppl 2): 6-10
4. Lescher GY, Froelich EJ, Gruett MD, Bailey JH and Brundage RP. 1,8-Naphthyridine derivatives: A new class of chemotherapy agents. J. Med. Pharm. Chem. (1962) 5: 1063–8
5. Appelbaum PC and Hunter PA. The fluoroquinolone antibacterials: Past, present and future perspectives. Int. J. Antimicrob. Agents (2000) 16: 5–15
6. Price JR. Some reactions of 1-methyl-4-quinolone-3- carboxylic acid, a degradation product of the alkaloids. Aust. J. Sci. Res. (1949) 2A: 272-281
7. Barton N, Crowther AF, Hepworth W, Richardson DN and Driver GW. New quinolones and therapeutic compositions containing them. GB 830832 (1960) [Chem. Abstr. (1961) 55: 7442e]
8. Wise R. Norfloxacin – a review of pharmacology and tissue penetration. J. Antimicrob. Chemother. (1984) 13 (Suppl. B): 59–64
9. Norris S, Mandell GL. The quinolones: History and overview. In: Andriole VT (ed.) The Quinolones. Academic Press, San Diego (1988) 1- 22
10. Norrby SR. Treatment of urinary tract infections with quinolone antimicrobial agents. In: Hooper DC, Wolfson JS (eds.) Quinolone Antimicrobial Agents. 2nd ed. American Society for Microbilogy, Washington DC (1993) 273-83
11. Domagala JM. Structure-activity and structure side effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. (1994) 33: 685–706
12. Tillotson GS, Blondeau JM. Structure–activity– function evaluation of the fluoroquinolones. In: Adam D, Finch RG, Hunter PA (eds.) Moxifloxacin in Practice. Maxim Medical, Oxford (1999) 91–101
13. Asahina Y, Ishizaki T and Suzue S. Recent advances in structure activity relationships in new quinolones. Prog. Drug Res. (1992) 38: 57–106
14. Tillotson GS. Quinolones: Structure–activity relationships and future predictions. J. Med. Microbiol. (1996) 44: 320–4
15. Ball P, Fernald A and Tillotson G. Therapeutic advances of new fluoroquinolones. Expert Opin. Inv. Drugs (1998) 7: 761–83
16. Koga H, Itoh A, Murayama S, Suzue S and Irikura T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline- 3-carboxylic acids. J. Med. Chem. (1980) 23: 1358-63
17. Jaillon P, Morganroth J, Brumpt I and Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J. Antimicrob. Chemother. (1996) 37 (Suppl. A): 161–7
18. Wiedemann B and Heisig P. Antibacterial activity of grepafloxacin. J. Antimicrob. Chemother. (1997) 40 (Suppl. A): 19–25
19. Lowe MN and Lamb HM. Gemifloxacin. Drugs (2000) 59: 1137–47
20. Ball P. Moxifloxacin (Avelox): An 8-methoxyquinolone antibacterial with enhanced potency. Int. J. Clin. Pract. (2000) 54: 329–32
21. Brighty KE and Gootz TD. The chemistry and biological profile of trovafloxacin. J. Antimicrob. Chemother. (1997) 39 (Suppl. B): 1–14
22. Dong Y, Xu C, Zhao X, Domagala J. and Drlica K. Fluoroquinolone action against mycobacteria: Effects of C-8 substituents on growth, survival, and resistance. Antimicrob. Agents Chemother. (1998) 42: 2978–84
23. Lu T, Zhao X and Drlica K. Gatifloxacin activity against quinolone-resistant gyrase: Allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob. Agents Chemother. (1999) 43: 2969–74
24. Cecchetti V, Fravolini A, Lorenzini MC, Tabarrini O, Terni P and Xin T. Studies on 6-aminoquinolones: Synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. J. Med. Chem. (1996) 39: 436–45
25. Ma Z, Chu DT, Cooper CS, Li Q, Fung AK, Wang S, Shen LL, Flamm RK, Nilius AM, Alder JD, Meulbroek JA and Or YS. Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: Consequences of structural modification at the C-8 position J. Med. Chem. (1999) 42: 4202–13
26. Spangler SK, Jacobs MR and Appelbaum PC. Susceptibility of anaerobic bacteria to trovafloxacin: Comparison with other quinolones and non-quinolone antibiotics. Infect. Dis. Clin. Pract. (1996) 5 (Suppl. 3): S101–9
27. Dalhoff A and Schmitz F-J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Did. (2003) 22: 203-221
28. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E and Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J. Antimicrob. Chemother. (2000) 45: 437–446
29. Garcia-Garrote F, Cercenado E, Martin-Pedroviejo J, Cuevas O and Bouza E. Comparative in-vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens. J. Antimicrob. Chemother. (2001) 47: 681– 684
30. Kim JH, Kang JA, Kim YG, Kim JW, Lee JH, Choi EC and Kim BK. In vitro and in-vivo antibacterial efficacies of CFC-222, a new fluoroquinolone. Antimicrob. Agents Chemother. (1997) 41: 2209–2213
31. Hooper D. Quinolones. In: Mandell GL, Bennett JE, Dolin R (eds.) Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases. 5th ed. Churchill Livingstone, Philadelphia (2000) 404-23
32. Hooper DC and Wolfson JS. Quinolone antimicrobial agents. 2d ed. American Society for Microbiology (1993) 53-7
33. Palù G, Valisena S, Ciarrocchi G, Gatto B and Palumbo M. Quinolone binding to DNA is mediated by magnesium ions. Proc. Natl. Acad. Sci. USA (1992) 89: 9671-5
34. De Sarro A and De Sarro G. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. Current Med. Chem. (2001) 8: 371-84
35. Domagala JM, Heifetz CL, Hutt MP, Mich TF, Nichols JB, Solomon M and Worth D F. 1-Substituted 7-[3- [(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro- 1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials. J. Med. Chem. (1988) 31: 991-1001
36. Chu DTW, Fernandes PB, Claiborne AK, Pihuleac E, Nordeen CW, Maleczka RE and Pernet AG. Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. J. Med. Chem. (1985) 28: 1558-64
37. Bryskier A and Chantot JF. Classification and structure-activity relationships of fluoroquinolones. Drugs (1995) 49: 16-28
38. Ohta M and Koga H. Three-dimensional structureactivity relationships and receptor mapping of N1- substituents of quinolone antibacterials. J. Med. Chem. (1991) 34: 131-9
39. Lawrence LE, Wu P, Fan L, Gouveia KE, Card A, Casperson M, Denbleyker K and Barret JF. The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J. Antimicrob. Chemother. (2001) 48: 195-201
40. Artico M, Mai A, Spardella G, Massa S, Musiu C, Lostia S, Demontis F and La Colla F. Nitroquinolones with broad-spectrum antimycobacterial activity invitro. Bioorg. Med. Chem. Lett. (1999) 9: 1651-6
41. Anderson VE and Osheroff N. Type II topoisomerases as targets for quinolone antibacterials. Curr. Pharm. Des. (2001) 7: 337-53
42. Shen LL, Mitscher LA, Sharma PN, O’Donnell T. J, Chu DWT, Cooper CS, Rosen T and Pernet AG. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug-DNA binding model. Biochemistry (1989) 28: 3886-94
43. Foroumadi A, Emami S, Davood A, Moshafi MH, Sharifian A, Tabatabaiee M, Tarhimi Farimani H, Sepehri G and Shafiee A. Synthesis and in-vitro antibacterial activities of N-substituted piperazinyl quinolones. Pharm. Sci. (1997) 3: 559-563
44. Foroumadi A, Emami S, Haghighat P and Moshafi MH. Synthesis and in-vitro antibacterial activity of new N-substituted piperazinyl quinolones. Pharm. Pharmacol. Commun. (1999) 5: 591-4
45. Foroumadi A, Davood A, Mirzaei M, Emami S and Moshafi MH. Synthesis and antibacterial activity of some novel N-substituted piperazinyl quinolones. Boll. Chim. Farm. (2001) 140: 411-16
46. Foroumadi A, Soltani F, Emami S and Davood A. Antituberclusis agents. III. In vitro evaluation of antimycobacterial activity and cytotoxicity of some Nsubstituted piperazinyl quinolones. Boll. Chim. Farm. (2002) 141: 247-9
47. Foroumadi A, Ashraf-Askari R, Moshafi MH and Emami S. Synthesis and in-vitro antibacterial activity of N-[5-(5-nitro-2-furyl)-1,3,4-thiadiazol-2-yl]piperazinyl quinolone derivatives. Pharmazie (2003) 58: 432-33
48. Mirzaei M and Foroumadi A. Synthesis and in-vitro antibacterial activity of N-piperazinyl quinolone derivatives with a 2-thienyl group. Pharm. Pharmacol. Commun. (2000) 6: 351-4
49. Foroumadi A, Mansouri S, Kiani Z and Rahmani A. Synthesis and in-vitro antibacterial evaluation of N-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolones. Eur. J. Med.Chem. (2003) 38: 851-4
50. Foroumadi A, Soltani F, Moshafi MH and Ashraf- Askari R. Synthesis and in-vitro antibacterial activity of some N-(5-aryl-1,3,4-thiadiazole-2-yl)piperazinyl quinolone derivatives. Il Farmaco (2003) 58: 1023- 28
51. Kondo H, Sakamoto F, Koders Y and Tsukamoto G. Studies on prodrugs. 5. Synthesis and antimicrobial activity of N-(oxoalkyl)norfloxacin derivatives. J. Med. Chem. (1986) 29: 2020-4
52. Fang K C, Chen Y L, Sheu J Y, Wang T C and Tzeng C C. Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives. J. Med. Chem. (2000) 43: 3809-12
53. Sheu J Y, Chen Y L and Tzeng C C. Synthesis, and antimycobacterial and cytotoxic evaluation of certain fluoroquinolone derivatives. Helv. Chim. Acta (2003) 86: 2481-9
54. Wise R, Andrews JM and Brenwald N. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone. J. Antimicrob. Chemother. (1993) 31: 73-80
55. Hong CY, Kim YK, Chang JH, Kim SH, Choi H, Nam DH, Kim YZ and Kwak JH. Novel fluoroquinolone antibacterial agents containing oxime-substituted (aminomethyl)pyrrolidines: Synthesis and antibacterial activity of 7-(4-(aminomethyl)-3- (methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl- 6- fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3- carboxylic acid (LB20304). J. Med. Chem. (1997) 40: 3584-93
56. Zhao X, Wang JY, Xu C, Dong Y, Zhou J and Domagala J and Drlica K. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob. Agents Chemother. (1998) 42: 956–8
57. Gootz TD and Brighty KE. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. Med. Res. Rev. (1996) 16: 433–86
58. Lipsky BA and Baker CA. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin. Infec. Dis. (1999) 28: 352–64
59. Blum MD, Graham DJ and McCloskey CA. Temafloxacin syndrome: Review of 95 cases. Clin. Infec. Dis. (1994) 18: 946–50
60. Ball P, Mandell L, Niki Y and Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety (1999) 21: 407–21
61. Yamamoto T, Tanida T, Ueta E, Kimura T, Doi S and Osaki T. Pulmonary infiltration with eosinophilia (PIE) syndrome induced by antibiotics, PIPC and TFLX during cancer treatment. Oral Oncology (2001) 37: 471–5
62. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H and Hoban DJ. A critical review of the fluoroquinolones: Focus on respiratory infections. Drugs (2002) 62: 13–59
63. Rubinstein E. History of quinolones and their side effects. Chemotherapy (2001) 47 (Suppl. 3): 3–8
64. Owens RC Jr and Ambrose PG. Clinical use of the fluoroquinolones. Med. Clin. North Am. (2000) 84: 1447-69
65. Ambrose PG, Owens RC Jr, Quintiliani R and Nightingale CH. New generations of quinolones: With particular attention to levofloxacin. Conn. Med. (1997) 61: 269-72
66. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. (2000) 30: 243-54
67. No authors listed. Gatifloxacin and moxifloxacin: Two new fluoroquinolones. Med. Lett. Drugs Ther. (2000) 42: 15-7
68. Eliopoulos GM. Activity of newer fluoroquinolones in-vitro against gram-positive bacteria. Drugs (1999) 58(suppl 2): 23-8
69. Applebaum PC. Quinolone activity against anaerobes. Drugs (1999) 58 (suppl 2): 60-4
70. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs (1999) 58: 11-8
71. Masecar BL, Clelesk RA and Robillard H. Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa. J. Antimicrob. Agents Chemother. (1990) 34: 281-6
72. Wolfson JS, Hooper DC. Mechanisms of killing of bacteria by 4-quinolones. In: Crumplin GG (ed.) The 4-Quinolones, Antibacterial Agents in vitro. Springer- Verlag, London (1990) 53-68
73. Ball P. Adverse drug reactions: Implications for the development of fluoroquinolones. J. Antimicrob. Chemother. (2003) 51 (Suppl. S1): 21-7
74. Jafri HS and McCracken GH Jr. Fluoroquinolones in paediatrics. Drugs (1999) 58: 43-8
75. Nicolle LE. Quinolones in the aged. Drugs (1999) 58: 49-51